Exosome Diagnostics and Treatment Market is expected to reach US$ 358 91 Mn by 2027 With Aethlon Medical, Inc , Therapeutic Solutions International, Inc , ReNeuron Group plc, Immune Therapy Holdings AB,And Others
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Activin A Market Research Report by Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Search jobs Rinri Therapeutics Appoints Terri Gaskell, PhD as Chief Technology Officer
Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announced the appointment of Dr. Terri Gaskell as its Chief Technology Officer (CTO) and member of the executive team. Dr. Gaskell brings over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
Terri joins from the UK Cell and Gene Therapy Catapult (CGTC) where she has worked for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGTC also included advising academics and small companies on the development of advanced therapies.
Published: Dec 18, 2020 By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk.